I just cut and paste this from where you can view the conference call - was always about arikace and now it's iplex.
Insmed Incorporated, a biopharmaceutical company, engages in the development of recombinant protein drug. The company’s primary product includes IPLEX, a complex of recombinant human IGF-1 and its binding protein IGFBP-3 for use in the treatment of various serious medical conditions, as well as conducting a phase III enabling clinical trial for investigating IPLEX as a treatment for myotonic muscular dystrophy. Insmed also engages in various oncology programs, including INSM-18, an orally available small molecule tyrosine kinase inhibitor that has demonstrated selective inhibition of IGF-1 and human epidermal growth factor receptor; and rhIGFBP-3, which is in early clinical development stage for the treatment of breast, prostate, liver, ovarian, and colon cancers. The company also provides Expanded Access Program in Italy to offer IPLEX to physicians for use in their patients with amyotrophic lateral sclerosis. It has a license to Pharmacia AB’s portfolio of regulatory filings pertaining to rhIGF; and an agreement with NAPO Pharmaceuticals that gives NAPO the right to develop, manufacture, and commercialize masoprocal products for various indications relating to diabetes, cardiac disease, vascular disease, metabolic disease, and syndrome X. The company was founded in 1999 and is based in Richmond, Virginia.